SCHEMBL14716159

SCHEMBL14716159

N#Cc1c2c(c(Cl)n3c1nc1ccccc13)CCC2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.65
NPSR1 Q6W5P4 5/20 0.64
KMT2A Q03164 4/20 0.64
MEN1 O00255 3/20 0.64
CYP1A2 P05177 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2C9 P11712 1/20 0.64
ATM Q13315 1/20 0.64
RXFP1 Q9HBX9 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
MAPT P10636 6/20 0.60
GAA P10253 3/20 0.60
HTT P42858 3/20 0.60
PKM P14618 2/20 0.60
CASP1 P29466 5/20 0.59
TSHR P16473 4/20 0.59
HSD17B10 Q99714 3/20 0.59
MAPK1 P28482 3/20 0.59
ALOX12 P18054 1/20 0.59
SMN1; SMN2 Q16637 5/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30630102 0.97 KDM4E (0.62) KDM4ENPSR1KMT2AMEN1CYP1A2
SCHEMBL14716146 0.84 KDM4E (0.51) KDM4ENPSR1KMT2AMEN1CYP1A2
SCHEMBL14728254 0.82 MAPT (0.52) KDM4ENPSR1KMT2AMEN1CYP1A2
SCHEMBL14728253 0.81 MAPT (0.56) KDM4ENPSR1KMT2AMEN1CYP1A2
SCHEMBL14728219 0.80 MAPK1 (0.77) KDM4ENPSR1KMT2AMEN1CYP1A2
SCHEMBL26702811 0.78 KDM4E (0.80) KDM4ENPSR1KMT2AMEN1CYP1A2
SCHEMBL14728385 0.77 MAPK1 (0.76) KDM4ENPSR1KMT2AMEN1CYP1A2
SCHEMBL26703074 0.77 KDM4E (0.75) KDM4ENPSR1KMT2AMEN1CYP1A2
SCHEMBL26608114 0.77 KDM4E (0.95) KDM4ENPSR1KMT2AMEN1CYP1A2
SCHEMBL14728693 0.77 KDM4E (0.59) KDM4ENPSR1KMT2AMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
EP-2565194-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2013-03-06 EP disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE PDE4B, PDE4A, PDE4C KDM4E 586/4885NPSR1 2690/4885KMT2A 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.